{
  "docId": "019de074-c46c-7261-862e-11078609bbd6",
  "docSlug": "94ed059236b735624310519badaf5152",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 32 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 32,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "Includes abbreviations for COPD, nOH, and PTE in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c46c-7261-862e-11078609bbd6/26",
  "deckHref": "/decks/019de074-c46c-7261-862e-11078609bbd6",
  "deckJsonHref": "/decks/019de074-c46c-7261-862e-11078609bbd6.json",
  "deckAnchorHref": "/decks/019de074-c46c-7261-862e-11078609bbd6#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.13,
        "y": 0.91
      },
      "kind": "subtitle",
      "text": "COPD, Chronic obstructive pulmonary disease; nOH, neurogenic orthostatic hypotension; PTE, patent term extensions.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11f2be13-26bf-428e-b12a-ead2722252d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.84,
        "x": 0.08,
        "y": 0.21
      },
      "kind": "table",
      "text": "Compound, Invention, Granted / Pending Application, Estimated Patent Expiry; YUPELRI / revefenacin, Composition of Matter, Granted US, 2028 (once PTE awarded); Polymorph, Granted US, 2030-2031; Method for the maintenance treatment of COPD patients, Granted US, 2039; Ampreloxetine, Composition of Matter, Granted US, 2030 (plus PTE of up to 5 years); Method of Treating nOH, Granted US, 2037",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f3e1b0d-619f-45df-b0a5-1addff97a919",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Patent Protection Into Late 2030s",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a17f1350-78b4-4e78-aaa5-20276cad10c4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}